Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–580.

• Crossref
• PubMed
Hirota S, Isozaki K, Moriyama Y, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–580.10.1126/science.279.5350.5779438854)| false
• Search Google Scholar
• Export Citation

Ma GL, Murphy JD, Martinez ME, et al. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev 2015;24:298–302.

• Crossref
• PubMed
Ma GL, Murphy JD, Martinez ME, Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev 2015;24:298–302.2527779510.1158/1055-9965.EPI-14-1002)| false
• Search Google Scholar
• Export Citation

Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005;100:162–168.

• Crossref
• PubMed
Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005;100:162–168.1565479610.1111/j.1572-0241.2005.40709.x)| false
• Search Google Scholar
• Export Citation

Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006;202:623–629.

• Crossref
• PubMed
Perez EA, Livingstone AS, Franceschi D, Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006;202:623–629.10.1016/j.jamcollsurg.2006.01.00216571433)| false
• Search Google Scholar
• Export Citation

Patel N, Benipal B. Incidence of gastrointestinal stromal tumors in the United States from 2001-2015: a United States cancer statistics analysis of 50 States. Cureus 2019;11:e4120.

• PubMed
Patel N, Benipal B. Incidence of gastrointestinal stromal tumors in the United States from 2001-2015: a United States cancer statistics analysis of 50 States. Cureus 2019;11:e4120.31037234)| false
• Search Google Scholar
• Export Citation

Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70–83.

• Crossref
• PubMed
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70–83.10.1053/j.semdp.2006.09.00117193820)| false
• Search Google Scholar
• Export Citation

Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466–477.

• Crossref
• PubMed
Dematteo RP, Heinrich MC, El-Rifai WM, Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466–477.10.1053/hupa.2002.12412212094371)| false
• Search Google Scholar
• Export Citation

Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–4349.

• Crossref
• PubMed
Heinrich MC, Corless CL, Demetri GD, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–4349.1464542310.1200/JCO.2003.04.190)| false
• Search Google Scholar
• Export Citation

Casali PG, Zalcberg J, Le Cesne A, et al. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. J Clin Oncol 2017;35:1713–1720.

• PubMed
Casali PG, Zalcberg J, Le Cesne A, Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. J Clin Oncol 2017;35:1713–1720.28362562)| false
• Search Google Scholar
• Export Citation

Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813–3825.

• Crossref
• PubMed
Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813–3825.1536507910.1200/JCO.2004.05.140)| false
• Search Google Scholar
• Export Citation

Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357–5364.

• Crossref
• PubMed
Corless CL, Schroeder A, Griffith D, PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357–5364.10.1200/JCO.2005.14.06815928335)| false
• Search Google Scholar
• Export Citation

Martin-Broto J, Martinez-Marín V, Serrano C, et al. Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis. Clin Transl Oncol 2017;19:536–545.

• Crossref
• PubMed
Martin-Broto J, Martinez-Marín V, Serrano C, Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis. Clin Transl Oncol 2017;19:536–545.10.1007/s12094-016-1581-227943096)| false
• Search Google Scholar
• Export Citation

Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093–1103.

• Crossref
• PubMed
Debiec-Rychter M, Sciot R, Le Cesne A, KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093–1103.1662455210.1016/j.ejca.2006.01.030)| false
• Search Google Scholar
• Export Citation

Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689–695.

• Crossref
• PubMed
Debiec-Rychter M, Dumez H, Judson I, Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689–695.10.1016/j.ejca.2003.11.02515010069)| false
• Search Google Scholar
• Export Citation

Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360–5367.

• PubMed
Heinrich MC, Owzar K, Corless CL, Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360–5367.)| false
• Search Google Scholar
• Export Citation

Patrikidou A, Domont J, Chabaud S, et al. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer 2016;52:173–180.

• Crossref
• PubMed
Patrikidou A, Domont J, Chabaud S, Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer 2016;52:173–180.10.1016/j.ejca.2015.10.06926687836)| false
• Search Google Scholar
• Export Citation

Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28:1247–1253.

• PubMed
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28:1247–1253.20124181)| false
• Search Google Scholar
• Export Citation

Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660–667.

• Crossref
• PubMed
Hirota S, Ohashi A, Nishida T, Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660–667.1294971110.1016/S0016-5085(03)01046-1)| false
• Search Google Scholar
• Export Citation

Cassier PA, Fumagalli E, Rutkowski P, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012;18:4458–4464.

• Crossref
• PubMed
Cassier PA, Fumagalli E, Rutkowski P, Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012;18:4458–4464.2271885910.1158/1078-0432.CCR-11-3025)| false
• Search Google Scholar
• Export Citation

Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol 2017;3:602–609.

• Crossref
• PubMed
Joensuu H, Wardelmann E, Sihto H, Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol 2017;3:602–609.10.1001/jamaoncol.2016.575128334365)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. Accessed August 16, 2022. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation

• PubMed
U.S. Food & Drug Administration. FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. Accessed August 16, 2022. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation)| false
• Search Google Scholar
• Export Citation

Ayvakit (avapritinib) tablets, for oral use [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; 2020.

• PubMed
Ayvakit (avapritinib) tablets, for oral use [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; 2020.)| false
• Search Google Scholar
• Export Citation

Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 2020;21:935–946.

• Crossref
• PubMed
Heinrich MC, Jones RL, von Mehren M, Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 2020;21:935–946.10.1016/S1470-2045(20)30269-232615108)| false
• Search Google Scholar
• Export Citation

Jones RL, Serrano C, von Mehren M, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer 2021;145:132–142.

• Crossref
• PubMed
Jones RL, Serrano C, von Mehren M, Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer 2021;145:132–142.10.1016/j.ejca.2020.12.00833465704)| false
• Search Google Scholar
• Export Citation

Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 2011;108:314–318.

• Crossref
• PubMed
Janeway KA, Kim SY, Lodish M, Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 2011;108:314–318.2117322010.1073/pnas.1009199108)| false
• Search Google Scholar
• Export Citation

Miettinen M, Wang ZF, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011;35:1712–1721.

• Crossref
• PubMed
Miettinen M, Wang ZF, Sarlomo-Rikala M, Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011;35:1712–1721.10.1097/PAS.0b013e318226075221997692)| false
• Search Google Scholar
• Export Citation

Heinrich MC, Rankin C, Blanke CD, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG intergroup trial S0033. JAMA Oncol 2017;3:944–952.

• Crossref
• PubMed
Heinrich MC, Rankin C, Blanke CD, Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG intergroup trial S0033. JAMA Oncol 2017;3:944–952.2819620710.1001/jamaoncol.2016.6728)| false
• Search Google Scholar
• Export Citation

Boikos SA, Pappo AS, Killian JK, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016;2:922–928.

• Crossref
• PubMed
Boikos SA, Pappo AS, Killian JK, Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016;2:922–928.2701103610.1001/jamaoncol.2016.0256)| false
• Search Google Scholar
• Export Citation

Liu W, Zeng X, Wu X, et al. Clinicopathologic study of succinate-dehydrogenase-deficient gastrointestinal stromal tumors: a single-institutional experience in China. Medicine (Baltimore) 2017;96:e7668.

• Crossref
• PubMed
Liu W, Zeng X, Wu X, Clinicopathologic study of succinate-dehydrogenase-deficient gastrointestinal stromal tumors: a single-institutional experience in China. Medicine (Baltimore) 2017;96:e7668.10.1097/MD.0000000000007668)| false
• Search Google Scholar
• Export Citation

Sutent (sunitinib malate) capsules, for oral use [prescribing information]. New York, NY: Pfizer Labs; 2021.

• PubMed
Sutent (sunitinib malate) capsules, for oral use [prescribing information]. New York, NY: Pfizer Labs; 2021.)| false
• Search Google Scholar
• Export Citation

Stivarga (regorafenib) tablets, for oral use [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2020.

• PubMed
Stivarga (regorafenib) tablets, for oral use [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2020.)| false
• Export Citation

Ben-Ami E, Barysauskas CM, von Mehren M, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol 2016;27:1794–1799.

• Crossref
• PubMed
Ben-Ami E, Barysauskas CM, von Mehren M, Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol 2016;27:1794–1799.10.1093/annonc/mdw22827371698)| false
• Search Google Scholar
• Export Citation

Ganjoo KN, Villalobos VM, Kamaya A, et al. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol 2014;25:236–240.

• Crossref
• PubMed
Ganjoo KN, Villalobos VM, Kamaya A, A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol 2014;25:236–240.10.1093/annonc/mdt48424356634)| false
• Search Google Scholar
• Export Citation

Votrient (pazopanib) tablets, for oral use [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021.

• PubMed
Votrient (pazopanib) tablets, for oral use [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021.)| false
• Search Google Scholar
• Export Citation

Yebra M, Bhargava S, Kumar A, et al. Establishment of patient-derived succinate dehydrogenase-deficient gastrointestinal stromal tumor models for predicting therapeutic response. Clin Cancer Res 2022;28:187–200.

• Crossref
• PubMed
Yebra M, Bhargava S, Kumar A, Establishment of patient-derived succinate dehydrogenase-deficient gastrointestinal stromal tumor models for predicting therapeutic response. Clin Cancer Res 2022;28:187–200.10.1158/1078-0432.CCR-21-209234426440)| false
• Search Google Scholar
• Export Citation

Lee JH, Shin SJ, Choe EA, et al. Tropomyosin-related kinase fusions in gastrointestinal stromal tumors. Cancers (Basel) 2022;14:2659.

• Crossref
• PubMed
Lee JH, Shin SJ, Choe EA, Tropomyosin-related kinase fusions in gastrointestinal stromal tumors. Cancers (Basel) 2022;14:2659.10.3390/cancers14112659)| false
• Search Google Scholar
• Export Citation

Brenca M, Rossi S, Polano M, et al. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol 2016;238:543–549.

• Crossref
• PubMed
Brenca M, Rossi S, Polano M, Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol 2016;238:543–549.2660688010.1002/path.4677)| false
• Search Google Scholar
• Export Citation

Shi E, Chmielecki J, Tang CM, et al. FGFR1 and NTRK3 actionable alterations in “wild-type” gastrointestinal stromal tumors. J Transl Med 2016;14:339.

• Crossref
• PubMed
Shi E, Chmielecki J, Tang CM, FGFR1 and NTRK3 actionable alterations in “wild-type” gastrointestinal stromal tumors. J Transl Med 2016;14:339.10.1186/s12967-016-1075-627974047)| false
• Search Google Scholar
• Export Citation

Vitrakvi (larotrectinib) capsules, for oral use [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2022.

• PubMed
Vitrakvi (larotrectinib) capsules, for oral use [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2022.)| false
• Search Google Scholar
• Export Citation

Rozlytrek (entrectinib) capsules, for oral use [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2021.

• PubMed
Rozlytrek (entrectinib) capsules, for oral use [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2021.)| false
• Search Google Scholar
• Export Citation

Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.

• Crossref
• PubMed
Drilon A, Laetsch TW, Kummar S, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.2946615610.1056/NEJMoa1714448)| false
• Search Google Scholar
• Export Citation

Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271–282.

• Crossref
• PubMed
Doebele RC, Drilon A, Paz-Ares L, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271–282.10.1016/S1470-2045(19)30691-6)| false
• Search Google Scholar
• Export Citation

Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008;47:853–859.

• Crossref
• PubMed
Agaram NP, Wong GC, Guo T, Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008;47:853–859.10.1002/gcc.2058918615679)| false
• Search Google Scholar
• Export Citation

Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 2010;133:141–148.

• Crossref
• PubMed
Hostein I, Faur N, Primois C, BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 2010;133:141–148.10.1309/AJCPPCKGA2QGBJ1R20023270)| false
• Search Google Scholar
• Export Citation

Maertens O, Prenen H, Debiec-Rychter M, et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 2006;15:1015–1023.

• Crossref
• PubMed
Maertens O, Prenen H, Debiec-Rychter M, Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 2006;15:1015–1023.1646133510.1093/hmg/ddl016)| false
• Search Google Scholar
• Export Citation

Belinsky MG, Rink L, Cai KQ, et al. Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case. BMC Cancer 2015;15:887.

• Crossref
• PubMed
Belinsky MG, Rink L, Cai KQ, Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case. BMC Cancer 2015;15:887.10.1186/s12885-015-1872-y)| false
• Search Google Scholar
• Export Citation

Burgoyne AM, De Siena M, Alkhuziem M, et al. Duodenal-jejunal flexure GI stromal tumor frequently heralds somatic NF1 and Notch pathway mutations. JCO Precis Oncol 2017;1:1–12.

• PubMed
Burgoyne AM, De Siena M, Alkhuziem M, Duodenal-jejunal flexure GI stromal tumor frequently heralds somatic NF1 and Notch pathway mutations. JCO Precis Oncol 2017;1:1–12.)| false
• Search Google Scholar
• Export Citation

Charo LM, Burgoyne AM, Fanta PT, et al. A novel PRKAR1B-BRAF fusion in gastrointestinal stromal tumor guides adjuvant treatment decision-making during pregnancy. J Natl Compr Canc Netw 2018;16:238–242.

• Crossref
• PubMed
Charo LM, Burgoyne AM, Fanta PT, A novel PRKAR1B-BRAF fusion in gastrointestinal stromal tumor guides adjuvant treatment decision-making during pregnancy. J Natl Compr Canc Netw 2018;16:238–242.10.6004/jnccn.2017.703929523662)| false
• Search Google Scholar
• Export Citation

NCI Staff. Dabrafenib-trametinib combination approved for solid tumors with BRAF mutations. Accessed August 16, 2022. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-dabrafenib-trametinib-braf-solid-tumors

• PubMed
NCI Staff. Dabrafenib-trametinib combination approved for solid tumors with BRAF mutations. Accessed August 16, 2022. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-dabrafenib-trametinib-braf-solid-tumors)| false
• Search Google Scholar
• Export Citation

Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352–5359.

• Crossref
• PubMed
Heinrich MC, Maki RG, Corless CL, Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352–5359.1895545810.1200/JCO.2007.15.7461)| false
• Search Google Scholar
• Export Citation

Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182–4190.

• Crossref
• PubMed
Antonescu CR, Besmer P, Guo T, Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182–4190.10.1158/1078-0432.CCR-04-224515930355)| false
• Search Google Scholar
• Export Citation

Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764–4774.

• Crossref
• PubMed
Heinrich MC, Corless CL, Blanke CD, Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764–4774.10.1200/JCO.2006.06.226516954519)| false
• Search Google Scholar
• Export Citation

Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006;12:1743–1749.

• Crossref
• PubMed
Wardelmann E, Merkelbach-Bruse S, Pauls K, Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006;12:1743–1749.1655185810.1158/1078-0432.CCR-05-1211)| false
• Search Google Scholar
• Export Citation

Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2007;13:5398–5405.

• Crossref
• PubMed
Desai J, Shankar S, Heinrich MC, Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2007;13:5398–5405.1787576910.1158/1078-0432.CCR-06-0858)| false
• Search Google Scholar
• Export Citation

Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751–1757.

• Crossref
• PubMed
Zalcberg JR, Verweij J, Casali PG, Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751–1757.10.1016/j.ejca.2005.04.03416098458)| false
• Search Google Scholar
• Export Citation

Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329–1338.

• Crossref
• PubMed
Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329–1338.10.1016/S0140-6736(06)69446-417046465)| false
• Search Google Scholar
• Export Citation

George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959–1968.

• Crossref
• PubMed
George S, Blay JY, Casali PG, Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959–1968.1928216910.1016/j.ejca.2009.02.011)| false
• Search Google Scholar
• Export Citation

Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer 2008;44:501–509.

• Crossref
• PubMed
Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer 2008;44:501–509.1823448810.1016/j.ejca.2007.11.021)| false
• Search Google Scholar
• Export Citation

Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367–1373.

• Crossref
• PubMed
Goodman VL, Rock EP, Dagher R, Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367–1373.10.1158/1078-0432.CCR-06-2328)| false
• Search Google Scholar
• Export Citation

Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 2009;106:1542–1547.

• Crossref
• PubMed
Gajiwala KS, Wu JC, Christensen J, KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 2009;106:1542–1547.10.1073/pnas.081241310619164557)| false
• Search Google Scholar
• Export Citation

Guo T, Hajdu M, Agaram NP, et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 2009;15:6862–6870.

• Crossref
• PubMed
Guo T, Hajdu M, Agaram NP, Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 2009;15:6862–6870.10.1158/1078-0432.CCR-09-1315)| false
• Search Google Scholar
• Export Citation

Nishida T, Takahashi T, Nishitani A, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol 2009;14:143–149.

• Crossref
• PubMed
Nishida T, Takahashi T, Nishitani A, Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol 2009;14:143–149.10.1007/s10147-008-0822-y19390946)| false
• Search Google Scholar
• Export Citation

Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295–302.

• Crossref
• PubMed
Demetri GD, Reichardt P, Kang YK, Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295–302.10.1016/S0140-6736(12)61857-123177515)| false
• Search Google Scholar
• Export Citation

Qinlock (ripretinib) tablets, for oral use [prescription information]. Waltham, MA: Deciphera, LLC; 2021.

• PubMed
Qinlock (ripretinib) tablets, for oral use [prescription information]. Waltham, MA: Deciphera, LLC; 2021.)| false
• Search Google Scholar
• Export Citation

Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:923–934.

• Crossref
• PubMed
Blay JY, Serrano C, Heinrich MC, Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:923–934.10.1016/S1470-2045(20)30168-632511981)| false
• Search Google Scholar
• Export Citation

Zalcberg JR, Heinrich MC, George S, et al. Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: an analysis of the INVICTUS study. Oncologist 2021;26:e2053–2060.

• Crossref
• PubMed
Zalcberg JR, Heinrich MC, George S, Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: an analysis of the INVICTUS study. Oncologist 2021;26:e2053–2060.3431337110.1002/onco.13917)| false
• Search Google Scholar
• Export Citation

Kindler HL, Campbell NP, Wroblewski K, et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago phase II consortium trial [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 10009.

• Crossref
• PubMed
Kindler HL, Campbell NP, Wroblewski K, Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago phase II consortium trial [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 10009.10.1200/jco.2011.29.15_suppl.10009)| false
• Search Google Scholar
• Export Citation

Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012;30:2377–2383.

• Crossref
• PubMed
Park SH, Ryu MH, Ryoo BY, Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012;30:2377–2383.10.1007/s10637-012-9795-922270258)| false
• Search Google Scholar
• Export Citation

Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: a retrospective analysis. Eur J Cancer 2013;49:1027–1031.

• Crossref
• PubMed
Montemurro M, Gelderblom H, Bitz U, Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: a retrospective analysis. Eur J Cancer 2013;49:1027–1031.10.1016/j.ejca.2012.10.00923140824)| false
• Search Google Scholar
• Export Citation

Kefeli U, Benekli M, Sevinc A, et al. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: a retrospective multicenter experience. Oncol Lett 2013;6:605–611.

• Crossref
• PubMed
Kefeli U, Benekli M, Sevinc A, Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: a retrospective multicenter experience. Oncol Lett 2013;6:605–611.10.3892/ol.2013.1408)| false
• Search Google Scholar
• Export Citation

Demetri GD, Casali PG, Blay JY, et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib- resistant gastrointestinal stromal tumors. Clin Cancer Res 2009;15:5910–5916.

• Crossref
• PubMed
Demetri GD, Casali PG, Blay JY, A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib- resistant gastrointestinal stromal tumors. Clin Cancer Res 2009;15:5910–5916.10.1158/1078-0432.CCR-09-0542)| false
• Search Google Scholar
• Export Citation

Montemurro M, Schöffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009;45:2293–2297.

• Crossref
• PubMed
Montemurro M, Schöffski P, Reichardt P, Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009;45:2293–2297.1946785710.1016/j.ejca.2009.04.030)| false
• Search Google Scholar
• Export Citation

Sawaki A, Nishida T, Doi T, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011;117:4633–4641.

• Crossref
• PubMed
Sawaki A, Nishida T, Doi T, Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011;117:4633–4641.2145600610.1002/cncr.26120)| false
• Search Google Scholar
• Export Citation

Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23:1680–1687.

• Crossref
• PubMed
Reichardt P, Blay JY, Gelderblom H, Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23:1680–1687.10.1093/annonc/mdr598)| false
• Search Google Scholar
• Export Citation

Cauchi C, Somaiah N, Engstrom PF, et al. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol 2012;69:977–982.

• Crossref
• PubMed
Cauchi C, Somaiah N, Engstrom PF, Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol 2012;69:977–982.2211975810.1007/s00280-011-1785-7)| false
• Search Google Scholar
• Export Citation

Blay JY, Shen L, Kang YK, et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 2015;16:550–560.

• Crossref
• PubMed
Blay JY, Shen L, Kang YK, Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 2015;16:550–560.2588298710.1016/S1470-2045(15)70105-1)| false
• Search Google Scholar
• Export Citation

Mir O, Cropet C, Toulmonde M, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 2016;17:632–641.

• Crossref
• PubMed
Mir O, Cropet C, Toulmonde M, Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 2016;17:632–641.2706885810.1016/S1470-2045(16)00075-9)| false
• Search Google Scholar
• Export Citation

Schöffski P, Mir O, Kasper B, et al. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’. Eur J Cancer 2020;134:62–74.

• PubMed
Schöffski P, Mir O, Kasper B, Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’. Eur J Cancer 2020;134:62–74.32470848)| false
• Search Google Scholar
• Export Citation

Schöffski P, Reichardt P, Blay JY, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 2010;21:1990–1998.

• Crossref
• PubMed
Schöffski P, Reichardt P, Blay JY, A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 2010;21:1990–1998.2050788110.1093/annonc/mdq076)| false
• Search Google Scholar
• Export Citation

Dewaele B, Wasag B, Cools J, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008;14:5749–5758.

• Crossref
• PubMed
Dewaele B, Wasag B, Cools J, Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008;14:5749–5758.1879408410.1158/1078-0432.CCR-08-0533)| false
• Search Google Scholar
• Export Citation

Trent JC, Wathen K, von Mehren M, et al. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST) [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 10006.

• Crossref
• PubMed
Trent JC, Wathen K, von Mehren M, A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST) [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 10006.10.1200/jco.2011.29.15_suppl.10006)| false
• Search Google Scholar
• Export Citation

Schuetze SM, Bolejack V, Thomas DG, et al. Association of dasatinib with progression-free survival among patients with advanced gastrointestinal stromal tumors resistant to imatinib. JAMA Oncol 2018;4:814–820.

• Crossref
• PubMed
Schuetze SM, Bolejack V, Thomas DG, Association of dasatinib with progression-free survival among patients with advanced gastrointestinal stromal tumors resistant to imatinib. JAMA Oncol 2018;4:814–820.10.1001/jamaoncol.2018.060129710216)| false
• Search Google Scholar
• Export Citation

Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 2019;35:738–751.e9.

• Crossref
• PubMed
Smith BD, Kaufman MD, Lu WP, Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 2019;35:738–751.e9.3108517510.1016/j.ccell.2019.04.006)| false
• Search Google Scholar
• Export Citation

Alkhuziem M, Burgoyne AM, Fanta PT, et al. The call of “the wild”-type GIST: it’s time for domestication. J Natl Compr Canc Netw 2017;15:551–554.

• Crossref
• PubMed
Alkhuziem M, Burgoyne AM, Fanta PT, The call of “the wild”-type GIST: it’s time for domestication. J Natl Compr Canc Netw 2017;15:551–554.10.6004/jnccn.2017.0057)| false
• Search Google Scholar
• Export Citation

Kato S, Adashek JJ, Shaya J, et al. Concomitant MEK and cyclin gene alterations: implications for response to targeted therapeutics. Clin Cancer Res 2021;27:2792–2797.

• Crossref
• PubMed
Kato S, Adashek JJ, Shaya J, Concomitant MEK and cyclin gene alterations: implications for response to targeted therapeutics. Clin Cancer Res 2021;27:2792–2797.3347291010.1158/1078-0432.CCR-20-3761)| false
• Search Google Scholar
• Export Citation